Puma Biotechnology
PBYI
174 hedge funds and large institutions have $2.13B invested in Puma Biotechnology in 2018 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 70 increasing their positions, 55 reducing their positions, and 27 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 55
0.97% more ownership
Funds ownership: 94.33% → 95.31% (+0.97%)
0% more call options, than puts
Call options by funds: $82.1M | Put options by funds: $82M
7% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 27
2% less funds holding
Funds holding: 178 → 174 (-4)
12% less capital invested
Capital invested by funds: $2.42B → $2.13B (-$295M)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$121M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$46M |
| 3 |
State Street
Boston,
Massachusetts
|
+$27.9M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$27.4M |
| 5 |
Jennison Associates
New York
|
+$27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$74.6M |
| 2 |
Janus Henderson Group
London,
|
-$68.4M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$34M |
| 4 |
D.E. Shaw & Co
New York
|
-$33.8M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$25.3M |
PBYI Hedge Fund Activity: Q2 2018 in Review
174 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q2 2018, worth a combined $2.13B — down 12% from $2.42B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of PBYI and 25 opened new positions — a net loss of 2 holders — while 55 trimmed existing stakes and 70 added.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $121M. The largest seller was Redmile Group, exiting entirely with an estimated $74.6M sold.
- 174 institutional investors held Puma Biotechnology (PBYI) as of Q2 2018, down from 178 in Q1 2018.
- Funds reported $2.13B of Puma Biotechnology stock for Q2 2018, down 12% quarter-over-quarter.
- 25 funds opened new Puma Biotechnology positions in Q2 2018 and 27 closed out, a net change of -2 holders.
- The largest Puma Biotechnology buyer in Q2 2018 was Consonance Capital Management, an estimated $121M added.
- The largest Puma Biotechnology seller in Q2 2018 was Redmile Group, an estimated $74.6M sold.
Based on aggregated 13F filings for Q2 2018.